MedTrace Logo

Titration Study of ABX-1431

NCT03447756 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2019-07-12

No results posted yet for this study

Summary

This study is designed to identify a titration regimen of ABX-1431 in adults with neuropathic pain with satisfactory tolerability to central nervous system (CNS) adverse events (AEs). During the course of this study, each participant will take a daily dose of ABX-1431 or a matching placebo for 28 days.

Conditions

  • Post Herpetic Neuralgia
  • Diabetic Peripheral Neuropathy
  • Small Fiber Neuropathy
  • Post-Traumatic Neuralgia

Interventions

DRUG

ABX-1431

Capsules of either 2mg, 10mg, or 50mg

DRUG

Placebo oral capsule

placebo to match

Sponsors & Collaborators

  • Abide Therapeutics

    lead INDUSTRY

Principal Investigators

  • Vitale Lisnic, PhD · ARENSIA EXPLORATORY MEDICINE

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-02
Primary Completion
2019-05-07
Completion
2019-05-07

Countries

  • Moldova

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03447756 on ClinicalTrials.gov